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Abstract  
The endogenous neurotransmitter dopamine (DA) is involved in several functions that are 
controlled from the central nervous system (CNS), for example behaviour, memory, cognition and 
reward. A disturbed dopaminergic neurotransmission may lead to many severe conditions, such as 
schizophrenia, attention deficit hyperactivity disorder (ADHD) or Parkinson's disease (PD). The 
dopamine receptors belong to the G-protein coupled receptors (GPCRs) and are divided into five 
distinct subtypes (D1-D5). These subtypes can be either of the D1- or D2-types based on their effect 
on the production of cyclic adenosine monophosphate (cAMP). The most common dopaminergic 
receptor used as target for pharmaceuticals is by far the D2 receptor and drugs acting as full 
agonists, partial agonists and antagonists at this receptor have been developed.  
In the search for new dopaminergic ligands, a set of 4-phenylpiperidines and 4-
phenylpiperazines have been synthesized and their effects have been tested in both in vivo and in 
vitro assays. Starting with the known partial agonist 3-(1-benzylpiperidin-4-yl)phenol, stepwise 
structural modifications of functional groups afforded mainly D2 antagonists but with a conserved 
preference for binding to the agonist binding site and fast dissociation rates from the receptor. 
However, further modifications, including changes of the position of the aromatic substituent, 
indicated that other targets than the D2 receptor was involved and binding affinity studies later 
concluded that some of these compounds had MAO A inhibiting properties. In order to fully 
elucidate what structural properties are related to the different pharmacological responses, QSAR 
models with physicochemical descriptors set against each respective response were acquired by 
means of partial least square (PLS) regression. Models with high predictivity (Q2>0.53) were obtained 
and the interpretation of these models has provided an improved understanding of how structural 
modifications in this chemical class affect the response both in vivo and in vitro. The structural 
motifs that were investigated included the position and physicochemical properties of the aromatic 
substituent as well as the heterocycle being a piperazine or a piperidine. All these properties turned 
out to be significant for the different responses in some aspect. In addition, a strong correlation 
between the affinities to the D2 receptor and to MAO A and the levels of the metabolite DOPAC in 
striatum has been established. This led us to the conclusion that it is primarily interactions with 
these two targets that lead to the in vivo response observed for this class of compounds.  
_______________________________________________________________________________ 
Keywords: dopamine, D2, monoamine oxidase, DOPAC, in vivo, QSAR, dopaminergic stabilizer 
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Abbreviations 
    
      
      
3-MT 
    
3-Methoxytyramine 
5-HT 
    
5-Hydroxytryptamine (serotonin) 
COMT 
    
Catechol-O-methyltransferase 
DA 
    
Dopamine 
DOPAC 
    
3,4-Dihydroxyphenylacetic acid 
EDG 
    
Electron donating group 
EWG 
    
Electron withdrawing group 
GPCR 
    
G-protein-coupled seven-transmembrane receptor 
HA 
    
Hydrogen bond acceptor 
HD 
    
Hydrogen bond donor 
HVA 
    
Homovanillic acid 
HPLC 
    
High performance liquid chromatography 
IA 
    
Intrinsic activity 
Ki 
    
Binding affinity constant 
LMA 
    
Locomotor activity 
NE 
    
Norepinephrine 
OPLS 
    
(Orthogonal) partial least square 
PD 
    
Parkinson’s disease. 
QSAR 
    
(Quantitative) structure-activity relationship 
VolR, 
    
Calculated volume. 
π 
    
Calculated hydrophobicity 
σm 
    
Hammett´s sigma meta 
σp 
    
Hammett´s sigma para 
µR 
    
Group dipole moment 
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1. INTRODUCTION 
 
1.1 Monoaminergic Neurotransmitters 
Neurotransmitters are a group of endogenous chemicals that transmit an impulse from a neuron to a 
target cell across a synaptic cleft. Neurotransmitters can be broadly split into two groups – the small 
molecule neurotransmitters and the relatively larger neuropeptide neurotransmitters. Within the 
category of small molecule neurotransmitters are the monoaminergic neurotransmitters, consisting 
of one amino group attached to an aromatic moiety by a two carbon chain. They are synthesized in 
the body from different amino acids (a.a.) and belong to specific subclasses depending on which 
a.a. they are derived from. The major monoamine subclasses active in the brain are the 
catecholamines and the tryptamines. Dopamine (DA, 1, Figure 1) and norepinephrine (NE, 2, 
Figure 1) belong to the catecholamines and serotonin (5-HT, 3, Figure 1) belongs to the tryptamine 
class.  
 
Figure 1. The monoamines: dopamine (1), norepinephrine (2) and serotonin/5-HT (3). 
 
1.1.1 Catecholamine Synthesis and Catabolism. Since the catecholamines are unable to penetrate 
the blood-brain barrier (BBB), they have to be synthesised in the brain by specific enzymes (Figure 
2). The precursor for catecholamine synthesis is tyrosine, an amino acid that is able to penetrate the 
BBB by a specific carrier. Tyrosine is oxidized to the catechol 3,4-dihydroxyphenylalanine (DOPA) 
by tyrosine hydroxylase and DOPA is then converted to dopamine (DA) by the enzyme aromatic L-
amino acid decarboxylase. Hydroxylation of DA by dopamine β-hydroxylase produce 
Norepinephrine (NE) and N-methylation by phenylethanolamine N-methyltransferas leads to 
epinephrine (E). However, from here on the focus of this work will be limited to dopamine. 
 
1 2 3
12 
 
 
Figure 2. The synthesis of catecholamines 
 
After being synthesized in the cytosol, dopamine is stored in presynaptic vesicles waiting for a 
signal. Neurotransmission occurs when an action potential causes the newly synthesised dopamine 
to be released into the synaptic cleft. There it activates post-synaptic receptors, which in turn 
propagate the signal further along the postsynaptic neuron. In addition, dopamine also affects pre-
synaptic receptors, resulting in a feed-back control of the continued synthesis and release of 
neurotransmitters into the synaptic cleft (Figure 3).  
Tyrosine
DOPA
Dopamine
Norepinephrine
Epinephrine
Aromatic L-amino acid decarboxylase
Dopamine β-hydroxylase
Phenylethanolamine N-methyltransferase
Tyrosine hydroxylase
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Figure 3. The dopamine neurone 
After exerting its effects at the synapse, dopamine is cleared from the synaptic cleft by either 
reuptake or degradation; leading to a termination of the signalling. The degradation of dopamine in 
the brain is primarily mediated through two enzymes: monoamine oxidase (MAO) and catechol-O-
methyl transferase (COMT). MAO metabolizes DA into 3,4-dihydroxyphenylacetaldehyde 
(DOPAL) which is further metabolized into 3,4-dihydroxyphenylacetic acid (DOPAC) by the 
enzyme aldehyde dehydrogenase (ALDH). COMT then methylates DOPAC to homovanillic acid 
(HVA), which is excreted via the urine. COMT is also able to directly metabolize dopamine, 
producing 3-methoxytyramine (3-MT) which in turn can be metabolized by MAO/ALDH into HVA 
(Figure 4).  
14 
 
 
Figure 4. Metabolism of dopamine (DA) into 3,4-dihydroxyphenylacetic acid (DOPAC), 3-
methoxytyramine (3-MT) and homovanillic acid (HVA) by monoamine oxidase (MAO), aldehyde 
dehydrogenase (ALDH) and catechol-O-methyl transferase (COMT). 
 
1.1.2. Monoamine Oxidases. There are two distinct types of MAOs, MAO A and MAO B, which 
share 70% amino acid sequence homology.
1-5
 They are tightly bound to the outer membrane of the 
mitochondrion in the liver and in the brain.
6
 Both MAO A and MAO B catalyze the oxidative 
deamination of 5-HT, DA and NA in the brain, albeit in rats this reaction is preferentially catalyzed 
by MAO A.
7, 8
 Furthermore, MAO A is the isoform found primarily within dopaminergic nerve 
terminals
9
 whereas MAO B is found mainly in striatal neurons and glial cells.
10
 Thus, in rats it is 
mainly MAO A that affect the DA catabolism leading to production of the metabolite DOPAC and 
therefore MAO A inhibitors (e.g. clorgyline) reduces striatal DOPAC levels in vivo.
6, 11
 In addition, 
when the MAO-mediated metabolism is blocked, more synaptic DA is metabolized by COMT to 3-
MT and less 3-MT is metabolized to HVA by MAO (Figure 3 and 4), leading to a concomitant 
increase in 3-MT levels.  
 
1.1.3. Dopamine Receptor Subtypes. In 1979, Kebabian et al. characterized two subtypes of the 
DA receptor as D1 and D2.
12
 The location and function of these two receptors has since then been 
extensively investigated.
13-17
 Even though there is some overlap in their distribution in the CNS, 
their pharmacological profiles are quite diverse. Both subtypes belong to the G-protein coupled 
3-MT
MAO
ALDH
COMT
COMT
DA
DOPAC
HVA
MAO
ALDH
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seven-transmembrane receptors (GPCRs), but where the D1 receptor interacts with the Gs type 
protein, resulting in an activation of the adenylate cyclase enzyme and subsequent increased 
production of cyclic adenosine monophosphate (cAMP), the D2 receptor instead interacts with the 
Gi complex, rendering an inhibition of the cAMP production. More recently, three additional 
subtypes of the DA receptor have been characterized, namely D3, D4 and D5. Based on their amino 
acid sequences and structural similarities, D5 has been identified as a D1-like receptor,
18
 while D3 
and D4 have been classified as D2-like.
13, 16, 17, 19, 20
 Sequencing has shown 75% similarity between 
the transmembrane regions of D2 and D3 while a corresponding number for D2/D4 is 53%.
21
 
However, even though the homology is high, studies on their respective distribution and function 
have revealed some substantial diversity between the different subtypes.
21
 This is also reflected in 
the respective in vivo responses of subtype specific compounds. For example, D3 agonists induce 
hypoactivity in rats at doses where the synthesis and release of DA is unaffected, providing 
evidence that D3 function mainly a postsynaptic receptor.
22-25
 The role of the D3 and D4 receptors in 
neuropsychiatric and neurological conditions have been studied extensively, and while D3 is 
claimed to be involved in several different brain disorders (e.g. schizophrenia, substance abuse etc.), 
the D4 receptor holds less promise as a drug target in this area.
21, 26, 27
    
 
 
1.1.4. The Dopamine D2 Receptor 
Dopamine type 2 receptors (D2) are mainly located in the structure of the mammalian brain known 
as the basal ganglia, but are also present in other areas, for example the cortex. Dopamine in the 
brain exerts its action by means of synaptic as well as extrasynaptic release, affecting postsynaptic, 
presynaptic and dendritic D2 receptor populations. DA acts as a high-affinity neurotransmitter at the 
D2 receptor allowing for low concentration tonic signalling of the dopaminergic system. In addition, 
the system can respond to short surges of DA evoked by event-related firing of the dopaminergic 
neurons.
21
 Two isoforms of the D2 receptor are generated by differential splicing of the same gene 
and have been termed D2S (D2-short) and D2L (D2-long).
28, 29
 These two alternatively spliced 
isoforms differ in the third intracellular loop (i.e. by the presence of 29 additional amino acids in 
D2L), causing some diversity in their anatomical, physiological, signaling, and pharmacological 
properties. D2S has been shown to be more densely expressed presynaptically and to be more 
involved in the autoreceptor functions, whereas D2L seems to be the main isoform 
16 
 
postsynaptically.
30, 31
 Presynaptic autoreceptors provide a negative feedback system that controls 
firing, synthesis and release of DA in response to extracellular neurotransmitter levels.
32-34
 Besides 
the different splice isoforms, the D2 receptor population can be distributed between two "activity-
states"; either a resting, low-affinity state (D2
Low
) or a catalytically active, high-affinity state (D2
High
) 
in which DA binds with higher affinity.
20, 35
  
 
1.2. Clinical Aspects of Dopaminergic Drugs 
DA was first recognized in 1958 by Arvid Carlsson and Nils-Åke Hillarp at the Laboratory for 
Chemical Pharmacology of the National Heart Institute of Sweden.
36
 Carlsson et al. demonstrated 
that reserpine depleted the levels of DA in the brain and that subsequent injection of L-DOPA 
restored these levels.
37
 Furthermore, reserpine was discovered to induce catalepsy in both rabbit and 
cat, and administration of L-DOPA gave an acute reversal of the said symptoms. These findings 
subsequently led to the theory of DA's role in the control of motor functions and possible 
involvement in the pathophysiology of Parkinson's disease (PD)
38
, a theory that was soon proven 
correct (Ehringer et al.
39
).  
Since the initial discovery of DA's presence in the brain, a great deal of effort has been made to 
investigate how DA affects the CNS, in the normal state as well as in disrupted systems. For 
example, the role of DA in the reward system has been extensively studied in order to understand 
addiction and finding suitable drugs to treat such disorders.
40-43
  
 
1.2.1. Schizophrenia. One of the fields where dopaminergic drugs have had the most profound 
impact is schizophrenia, where the DA hypothesis for a long time has been the leading 
pathophysiologic theory, and DA blocking drugs has been the standard treatment since the 1950's. 
Schizophrenia is a severe, world-wide disease affecting about 1% of the population. The symptoms 
are divided into positive (hallucinations, delusions etc.), negative (lack of motivation, anhedonia, 
etc.) and cognitive (memory- and attention-deficits).
44
 The search for an ideal treatment of 
schizophrenia has moved from D2-antagonists (e.g. haloperidol (6) and chlorpromazine) introduced 
in the 1950's,
45, 46
 to atypical antipsychotics of various types and with a broad spectrum of 
mechanisms (e.g. clozapine, aripirazole etc.).
47
 Although traditional D2-antagonist antipsychotics 
are efficacious for the positive symptoms, they are also responsible for extrapyramidal side effects 
17 
 
(EPS) which occur as a result of excessive attenuation of brain DA neuronal activity due to the 
blockade of postsynaptic DA receptors.
48, 49
  
 
1.2.2. Neurological Diseases. As mentioned earlier, PD was the first disease where the involvement 
of DA in the brain was proven, and L-DOPA is still the main treatment for this condition. Since 
then, the importance of DA for both motor and cognitive functions in the patophysiology of many 
neurological diseases and disorders has been understood. Besides PD, dopaminergic drugs have also 
been found useful in the treatment of Huntington´s disease (HD), restless leg syndrome (RLS), 
Tourette's syndrome and attention deficit hyperactivity disorder (ADHD).  The pharmacological 
profiles of the drugs used to treat these disorders are quite diverse, from DA antagonists in RLS and 
Tourette's syndrome to DA reuptake inhibitors in ADHD. In HD, the vesicular monoamine 
transporter (VMAT)-inhibitor tetrabenazine has shown to be effective in treatment of chorea.
50
 
However, there are many aspects of this disease and an effective treatment option for other 
symptoms is still being sought for. Recent clinical trials have shown promising results for the 
dopaminergic stabilizer pridopidine (ACR16, Huntexil®) (16, Figure 7) with beneficial effects on 
several manifestations of HD and a very favorable side effect profile.  
 
1.3. Dopamine D2 Ligands 
Drugs that interact with the agonist binding site of D2 receptors can be described as full agonists, 
partial agonists or antagonists/inverse agonists
51
 and a number of such drugs have well-established 
applications in the treatment of various neurological and psychiatric disorders. The association and 
dissociation rate constants, kon and koff, besides defining the equilibrium state also describe how fast 
the ligand associate to and dissociate from the receptor system. Moreover, it has been proposed that 
the occurrence of side effects (e.g. extrapyramidal symptoms and sustained hyperprolactinaemia) of 
antipsychotic drugs is directly linked to the long D2 dissociation rates.
52-54
 
 
1.3.1. DA D2 Agonists. In vitro, the D2 agonists preferentially displaces agonist ligands over 
antagonist ligands in binding assays and induce a full catalytic reaction in functional assays (i.e. 
they have high intrinsic activity).
55-57
 In vivo, the full D2 agonists induce a decrease in DA release 
18 
 
through activation of presynaptic autoreceptors and affect locomotor activity in a biphasic manner 
(i.e. first decreased, then increased activity). The biphasic effect on behaviour is dose dependent and 
caused by differences in sensitivity between the autoreceptors and the postsynaptic receptors. In 
general, the autoreceptors are more sensitive and low doses of agonist only activate this population, 
leading to a decrease in DA release and a concomitant diminished locomotor activity. At higher 
doses, postsynaptic receptors are also affected with behavioural stimulation as a result. Examples of 
full D2 agonists are DA (1), quinpirole (4) and ropinirole (5). 
 
1.3.2. DA D2 Antagonists. In contrast to the agonists, the D2 antagonists in general show no 
preference in displacing agonist over antagonist ligands in binding assays and they induce no 
catalytic reaction in functional assays. In vivo, D2 antagonists induce an increase in DA release 
through blockage of presynaptic autoreceptors and decreased locomotor activity through inhibition 
of postsynaptic receptors. D2 antagonists are by far the most common type of dopaminergic ligands 
in medicine, for example haloperidol (6) and risperidone (7) used to treat schizophrenia (Figure 5).  
 
Figure 5. Dopamine antagonists haloperidol (6), risperidone (7) clozapine (8) and quetiapine (9). 
 
4 5
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1.3.3. DA D2 Partial Agonists. D2 partial agonists, much like full agonists, in general 
preferentially displace agonist ligands over antagonist ligands in binding assays.
58
 However, the 
partial agonists do not induce a full catalytic response in functional assays (i.e. they have lower 
intrinsic activity than the full agonist). In vivo, partial D2 agonists affect DA release and locomotor 
activity differently depending on the level of intrinsic activity. If the level of intrinsic activity is 
very low, the in vivo effects are similar to those of an antagonist while higher intrinsic activity 
induces more agonist-like effects. The D2 partial agonist aripiprazole (10, Figure 6) has very low 
intrinsic activity
59, 60
 and is therefore thought to act as either a functional agonist or a functional 
antagonist, depending on the initial levels of DA. Aripiprazole has been approved for the treatment 
of schizophrenia, bipolar disorder and depression. 
 
Figure 6. Dopamine partial agonists aripiprazole (10), (–)-3PPP (11), bifeprunox (12), piribedil (13) and 
pardoprunox (14). 
 
1.3.4. Dopaminergic Stabilizers. For the last decades the bulk of medicinal chemistry 
optimization programs have generated high-affinity drugs with slow drug–receptor kinetics. In the 
meantime, limited attention has been set on optimizing D2 ligands with low in vitro affinity and 
receptor kinetics comparable to those of natural DA signaling. Studies have shown that DA D2 
receptor kinetics differs among antipsychotic compounds and it has been proposed that fast-off 
kinetics (high koff) is a requirement for atypicality.
54, 61
 This is a new approach towards determining 
what properties are important in order to achieve an optimal antipsychotic profile with low 
propensity for side effects and the dopaminergic stabilizers have been characterized in vitro as low 
 
13 14
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affinity D2 receptor ligands with fast-off receptor kinetics.
62, 63
 It is however the in vivo effect that 
singles out the dopaminergic stabilizers from other D2 ligands, having the ability to counteract 
states of both hyperactivity and hypoactivity, depending on the prevailing dopaminergic tone. To 
date, four dopaminergic stabilizers have been developed, namely (3S)-3-(3-methylsulfonylphenyl)-
1-propylpiperidine ((-)-OSU-6162; 15, Figure 7), 4-(3-methylsulfonylphenyl)-1-propylpiperidine 
(pridopidine; 16, Figure 7), 1-ethyl-4-(2-fluoro-3-methylsulfonyl-phenyl)piperidine (ordopidine; 17, 
Figure 7) and 1-ethyl-4-(3-fluoro-5-methylsulfonyl-phenyl)piperidine (seridopidine; 18, Figure 7). 
Pridopidine has shown unique effects in clinical studies for symptomatic treatment of Huntington´s 
disease (HD) while 15 is being tested for treatment of alcohol dependence.
64
 Other areas where 
dopaminergic stabilizers have shown promising results are PD, L-DOPA induced dyskinesia (LID), 
schizophrenia and stroke/traumatic brain injury.
65, 66
 
 
 
 
Figure 7. Dopaminergic stabilizers S-(-)-OSU6162 (15), pridopidine (16), ordopidine (17) 
and seridopidine (18). 
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1.4. Structure Activity Relationships  
Structure activity relationships (SARs) describe the relationship between the structure of a molecule 
and its biological/pharmacological activity. There are different ways to describe a molecule and 
thus different ways to produce a SAR, for example using the 3D-structure or physicochemical 
properties of parts of, or the entire, molecule. The biological/pharmacological activity also includes 
a wide range of different parameters, like in vitro affinity to a certain receptor or the locomotor 
activity of a living animal. The SAR enables the medicinal chemist to understand how chemical 
modifications affect the biological response and this knowledge can be used to produce new 
compounds with a desired profile.  
 
1.4.1 Phenylpiperidines and Phenylpiperazines. As structural backbones for pharmacologically 
active compounds, phenylpiperidines and phenylpiperazines have been extensively studied for 
several different targets. For example, many 5-HT ligands are based on these structures, like the 5-
HT1A agonist fluprazine (19), the SSRI paroxetine (20) and the 5-HT2A antagonist nefazodone (21). 
 
Other targets where phenylpiperidines and phenylpiperazines have been investigated as potential 
ligand scaffolds include GABA, NMDA and the adrenergic receptors. However, the main use of 
these structures in medicinal chemistry has been as dopaminergic ligands. Haloperidol (6), as 
 
21
19 20
22 
 
mentioned previously, is a D2 antagonist and one of the first classical neuroleptics used as a 
treatment option in schizophrenia. Since then, many 4-phenylpiperidine analogues have been 
studied for their dopaminergic effects and potential use as antipsychotics. The partial D2 agonists 
aripiprazole (10) and bifeprunox (12) instead have the phenylpiperazine backbone and a lot of 
attention has been devoted to find D2/D3 ligands in this structural class. Most series of 
phenylpiperidines and –piperazines acting on the D2/D3 receptors have an additional aromatic 
moiety attached at the basic amine and a linker of varying length in between. The linker has proved 
important for the D2/D3 selectivity and recent publications have concluded that the binding cavity in 
the extracellular loop region of D2 is significantly shallower than the D3 counterpart.
67, 68
 The same 
group also reported compounds selective for both D2 (SV-III-130s (22) and SV293 (23))
67
 and D3 
(24)
69
 receptors, but for most D2-type ligands the affinities to these subtypes are similar. The D4-
ligand L-745870 (25)
70
 is also of the phenylpiperazine class and the bulky N-substituent is proposed 
to be favorable for selectivity over D2.          
 
 
1.4.2. D2 Ligands. Most compounds affecting the D2 receptor has at least one aromatic moiety and 
one basic amine. In general, the agonists are relatively small, hydrophilic molecules whereas the 
antagonists are usually larger and more lipophilic.
71
 Furthermore, the full agonists have certain 
pharmacophore elements that usually are required in order to achieve a full catalytic response at the 
D2 receptor, for example a hydrogen bonding aromatic substituent (preferable in the meta position) 
and the basic amine in a position that resembles that of DA itself (e.g. 5-OH-DPAT (26) and 
 
23
2524
22
23 
 
quinpirole (4)).
58
 The D2 receptor antagonists bind to the receptor but do not activate the G-protein 
and these compounds are usually of a bulky and hydrophobic character. D2 receptor antagonists 
usually consist of two aromatic moieties with a basic amine in between (e.g. haloperidol (6) and 
risperidone (7)) and molecular modelling based on closely related receptor structures (i.e. D3 and 
β2) have confirmed that hydrophobic interactions of the aromatic parts stabilize the inactive 
conformation.
72, 73
  
The SAR of partial D2 agonists is more complex and both small and hydrophilic and bulky and 
hydrophobic structures with this profile have been developed. 3-[(3S)-1-Propyl-3-piperidyl]phenol 
((–)-3PPP; 11) is a partial agonist while the corresponding R-enantiomer (27) is a full agonist74 and 
alignment of these two molecules with rigid full agonist analogues has revealed that the R-
enantiomer fits perfectly while the aromatic ring and basic nitrogen of the S-enantiomer are unable 
to adapt the "right" conformation.
58, 74
 3-(4-Benzylpiperazin-1-yl)phenol (29) first published by 
Mewshaw et al.
75
 lack the phenethylamine backbone of DA but still has intrinsic activity. The SAR 
of the phenylpiperazines indicated that a hydrogen-bonding group in the meta-position was 
preferred for the agonist properties and that the N-substituent could be either a small alkyl or a large 
aromatic group. The partial D2 agonists, bifeprunox (12) and pardoprunox (14), are based on the 
phenylpiperazine backbone and have a benzoxazolone-group on the aromatic ring with the 
hydrogen-bonding functionality in the meta-position. Pardoprunox has a small methyl-group on the 
piperazine while bifeprunox has a bulky biphenyl-moiety, yet the intrinsic activity of the two 
analogues is similar.
76-78
  The aripiprazole structure contains a 2,3-dichloro-substituted 
phenylpiperazine moiety that has been shown to stabilize the active conformation of the D2 receptor 
through a hydrogen-bond between the 3-chloro group and a serine in the active site.
79
 Recent 
studies have also shown that the chlorine-oxygen interaction can be relevant for binding affinities
80
 
albeit not as strong as the hydrogen bonding between a "full" hydrogen donor and acceptor. A 
weaker interaction with the receptor is a possible explanation to the fact that although aripiprazole 
act as a partial agonist, it has lower intrinsic activity than for example bifeprunox or (–)-3PPP. It 
should however be noted that even if a hydrogen-bonding substituent in the meta-position is 
positive for intrinsic activity, it is not essential.  The π-π interactions are also likely to be important 
for the stabilization of the active conformation and the fact that (S)-2-dipropylaminotetralin (S-
DPAT, 28), which lack aromatic substituents, acts as a full DA D2 agonist is a strong indication for 
this.
56, 58
 Moreover, this could explain the intrinsic activity of piribedil (13)
81
 as well as the fact that 
the 2-methoxy analogue of aripiprazole also act as a partial agonist.
82
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1.4.3. MAO Inhibitors. Compounds that bind to and block the effect of MAO can be divided into 
reversible or irreversible inhibitors. Furthermore, the inhibitors can be selective for either MAO A 
or MAO B or non-selective (having equal effects on both isozymes). As an entity, the MAO 
inhibitors (MAOIs) are structurally quite diverse, but there is a distinct separation between 
reversible and irreversible inhibitors. While the irreversible inhibitors, for example ipronazid (30, 
Figure 8) and selegiline (31, Figure 8), have a functional group (e.g. propargylamine or hydrazine) 
that enables covalent binding to the enzyme, the reversible inhibitors lack such moiety. Structural 
separations between MAO A and MAO B is less evident, but most reversible MAO A inhibitors 
have an aromatic moiety with a basic amino group at 2-4 atoms distance from the ring (e.g. 
moclobemide (32, Figure 8) and pirlindole (33, Figure 8). Studies on para-substituted 
phenethylamines, benzylamines and amphetamines have shown that the physiochemical properties 
of the para-substituent are correlated to the affinity of the two isozymes. Size and electronic 
properties have been proposed to mainly impact affinity to MAO A, while the hydrophobicity of the 
substituent seems to influence MAO B affinity to a greater extent.  
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Figure 8. Irreversible MAOIs: iproniazid (30) and selegiline (31). Reversible MAO A 
inhibitors moclobemide (32) and pirlindole (33).  
 
1.4.4. Quantitative structure activity relationships (QSARs). SAR is useful when comparing 
heterogeneous structural classes with diverse biological activities. There is however a shortcoming 
with this method; it assumes that similar molecules have similar activities. This is indeed not 
always the case, since many times small differences on the molecular level can have a major impact 
on the response. In order to find relationships between a homogenous group of compounds and their 
respective activity, quantitative structure activity relationships (QSARs) can instead be applied. 
QSAR models attempt to relate chemical structure to biological activity using quantitative 
regression by setting the chemical properties of a molecule, or parts thereof (e.g. Hammett constants 
of a substituent) against the response variable of a biological activity (e.g. affinity to a receptor). 
QSAR modeling generally involves three steps: (1) design of a training set of molecules; (2) 
decision on descriptors that are presumed relevant for the correlation between chemical structure 
and biological activity; and (3) application of statistical methods that correlate changes in structure 
with changes in biological activity. Since in QSAR, the physicochemical properties of chemical 
structures as well as biological response are expressed by numbers, a mathematical relationship can 
be established between the two. The model can then be used to predict the biological activity of new 
chemical structures and is therefore a powerful tool in medicinal chemistry.  
Most QSAR models in the field are based on in vitro data as the biological response, or more 
specifically, binding affinities to one or many receptors. It has been a general resistance towards 
 
30
33
32
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using in vivo data in QSAR modeling, mostly derived from a skeptic view on the response obtained 
from a complex biological system such as a living animal. The data from an in vivo experiment is 
often linked to several different aspects of pharmacology, pharmacodynamics and 
pharmacokinetics, and therefore each specific contribution can be difficult to interpret. However, 
the sum of these aspects for the most part holds very valuable information and an in vivo response 
can even be superior to in vitro data in a QSAR model.     
 
1.4.5. Drug Design. In drug design the knowledge of biological targets, usually proteins and 
enzymes in pathways that are related to a particular disease state, is used to find new drugs that 
affect these targets in a specific way. There are many different techniques that can be used to obtain 
this knowledge. The application of X-ray crystallography and NMR spectroscopic methods can 
resolve the structure of proteins to a very high resolution, making it possible to determine its 3D- 
structure. This information can in turn provide valuable insight into the optimization of the 
molecular interactions of a drug-target complex to achieve potency and selectivity of a drug 
candidate. However, in order to acquire the 3D-structure of a target protein, it has to be in a 
crystalline form and many biological targets are extremely difficult to crystallize. Especially the 
trans-membrane proteins have been problematic in this aspect, the main reason being the 
amphipathic nature of their surface. Instead computerized modeling, using the amino acid sequence 
of the target protein together with known 3D geometrical shape of homologue proteins, can be 
applied. 
The 3D-structures of both MAO A and MAO B have been determined by X-ray crystallography 
with several different ligands
83-86
 and these structures have been used in the development of novel 
classes of MAO inhibitors.
87-89
 DA D2, on the other hand, has not yet been successfully crystallized, 
but molecular modeling based on the 3D structure of the closely related DA D3
72
 and β2 
adrenergic
90, 91
 receptors has provided a better understanding of the ligand-receptor interactions in 
this class.
79, 92, 93
 These studies have revealed that Asp-114 on the third transmembrane helix (TM3) 
most likely forms of a salt bridge with the protonated nitrogen of DA and that serine residues in 
TM5 (Ser-193, Ser-194 and Ser-197) interact with the catechol function through hydrogen bonding 
(Figure 9).
94-99
 More recent publications have also shown that His-393 on TM6 can form hydrogen 
bonds with the catechol or other hydrogen bonding groups of dopaminergic ligands.
92, 100
 In 
addition, Phe-110, Met-117, Cys-118 (TM3), Phe-164 (TM4), Phe-189, Val-190 (TM5), Trp-386, 
Phe-389, Phe-390, and His-394 (TM6) contribute to the stabilization of the drug-receptor complex 
27 
 
via hydrophobic interactions.
92, 100
 Ligand interactions with two amino acids, Ile-184 and Asn-186, 
in the second extracellular loop (EC2) have also shown to be important (Figure 9).
92, 101
 It has been 
proposed that in the activation phase of GPCRs, TM6 undergoes a translational or rotational 
movement, and that the interaction with an agonist facilitates this movement.
102-105
 In line with this 
proposal, Goddard et al. (2007) speculated that DA D2 agonists interact with TM3 (Asp-114) and 
TM5 (Ser-193 and Ser-197) by pulling them closer together in the active state, allowing the flexible 
motion of TM6.
106
 An antagonist (such as haloperidol) instead interacts strongly with TM3 and 
TM6 (having minimal contact with TM5), thus preventing such movement.
99, 106
 
 
 
 
Figure 9. Schematic view of the interactions between the full agonist (R)-2-OH-NPA and the DA D2 
receptor in a homology model by Malo et al.
92
 Amino acids in purple are polar, while green residues 
are hydrophobic. The blue shades indicate ligand–receptor solvent accessibility. 
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2. AIMS 
 
This work is a part of a research project aimed at finding novel dopaminergic ligands with 
beneficial effects in several neurological and psychiatric disorders. The discovery and mechanism 
of action of the dopaminergic stabilizer pridopidine (ACR16, Huntexil®, 16), currently being 
developed for Huntington's disease, are included. In addition, the QSARs of mono-substituted 4-
phenylpiperidines/-piperazines have been investigated and correlations between the in vivo and in 
vitro profile of compounds in this structural class has been established.  
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3. CHEMISTRY (Papers I, II and III) 
The compounds included in this work have been synthesized by various methods described in the 
literature. Alkylation of commercially available phenylpiperazines/-piperidines using standard 
conditions (Scheme 1) produced the bulk of target compounds. Other methods were applied when 
the desired starting material was unavailable, and these methods are shown in separate sections. 
 
     Scheme 1 
 
a 
Reagents and conditions: (a) PrI or BnBr, K2CO3, CH3CN, ∆. 
 
3.1. Original Synthetic Route to Pridopidine (Paper I) 
Pridopidine (16), or ACR16 as the compound was first named, has recently been developed for 
large scale manufacturing and is currently being synthesized with an optimized synthetic route. 
However, the first synthesis of pridopidine/ACR16 was performed by a different route (Scheme 2, 
R=Pr). In the first step of seven in total, 1-bromo-3-methylthiobenzene was treated with n-
butyllithium and quenched with 1-Boc-4-piperidone to yield 34. Subsequent treatment with 
trifluoroacetic acid (TFA) in a solution of DCM led to both deprotection and dehydroxylation, 
producing 35 in excellent yield. It is well known in the trait that sulfides contaminate the palladium 
of the Pd/C-catalyst used in H2-mediated reductions,
107
 and therefore the sulfide had to be oxidized 
to the corresponding sulfone prior to the reduction step. Attempts to oxidize 35 directly with m-
chloroperbenzoic acid (m-CPBA) did however lead to simultaneous oxidation of the 
tetrahydropyridine-ring along with the thiomethyl-group, producing the undesired 4-[3-
(methylsulfonyl)phenyl]pyridine. In order to avoid this side-reaction, 35 was first protected by the 
addition of methylchloroformate to afford the carbamate 36, after which quantitative oxidization by 
m-CPBA to the corresponding sulfone 37 was possible. 37 was then easily reduced with catalytic 
 
X = N, CH
R' = n-Pr, Bn
R = H, OMe, SO2Me, CN, Me, Cl, OH, CF3, COMe, Ot-Bu
a
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hydrogenation (Pd/C), affording the piperidine-derivative 38 in good yield. After the deprotection 
of 38 with aqueous HCl (8 M), the secondary amine 39 was alkylated with 1-iodopropane, affording 
pridopidine/ACR16 (16) (Scheme 2). The corresponding benzyl-analogue (40) was obtained by 
alkylation of 39 with benzylbromide. In addition, the preparation of 4-(3-
isopropylsulfonylphenyl)piperidine (87) followed the same synthetic route. 
 
 Scheme 2    
 
a 
Reagents and conditions: (a) n-butyllithium, 1-Boc-4-piperidone, THF; (b) trifluoroacetic acid, CH2Cl2, ∆; 
(c) triethylamine, methylchloroformate, CH2Cl2; (d) m-CPBA, CH2Cl2; (e) Pd/C, H2, MeOH, HCl; (f) HCl, 
EtOH, ∆; (g) PrI or BnBr, K2CO3, CH3CN,  
 
 
 
 
 
34 35 36
37 38
39
16 R=Pr
40 R=Bn
g
a b c
d
e f
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3.2. Suzuki Cross Coupling between Phenylbromides and 1-Pyridyl-4-boronic acid (Paper III) 
The Suzuki cross coupling is a palladium catalyzed cross-coupling reaction between organic halides 
and organoboron compounds that leads to the formation of carbon-carbon bonds.
108-110
 The 
mechanism of the Suzuki reaction has been studied extensively in order to fully optimize the 
reaction conditions (Figure 10).
111
 The first step is an oxidative addition of palladium to the halide 
(I) which forms an organo-palladium complex (II). Further reaction with the required base (e.g. 
Na2CO3, K3PO4) gives an intermediate (III), which via transmetalation with the boronate complex 
(V) forms another organo-palladium species (VII). Reductive elimination yields the desired product 
(VIII) and restores the original palladium catalyst (IX) for further use. 
 
            Figure 10. The proposed mechanism for the Suzuki cross coupling reaction. 
 
In the cases were the desired phenylpiperidine starting material was commercially unavailable and  
lithiation or Grignard reaction of the phenylbromide was inapplicable (see Scheme 2), the desired 
phenylpiperidines were  acquired through Suzuki cross-coupling of the substituted arylbromides 
and 4-pyridineboronic acid, followed by reduction of the pyridine ring (Scheme 2).  
4-[3-(Trifluoromethylsulfonyl)phenyl]pyrididine (41), 4-[3-(4-pyridyl)phenyl]morpholine (42) , 4-
(3-cyclopentylsulfonylphenyl)pyridine (43) and 4-(4-Methylsulfonylphenyl)pyridine (44) were all 
prepared through Suzuki-coupling, but only the pyridine ring of 41 could be reduced directly by 
platina-mediated catalytic hydrogenation.
112
 For the other substrates this reaction was unsuccessful 
and instead quarterisation of the pyridine nitrogen by heating with 1-iodopropane preceded the 
34 
 
reduction.
113
 Thus, the desired target compounds 4-(3-cyclopentylsulfonylphenyl)-1-
propylpiperidine (46), 4-[3-(1-propyl-4-piperidyl)phenyl]morpholine (47) and 4-(4-
methylsulfonylphenyl)-1-propylpiperidine (48) were obtained from the reduction step, while a 
subsequent N-propylation produced 1-propyl-4-[3-(trifluoromethylsulfonyl)phenyl]piperidine (45). 
 
Scheme 3 
 
a 
Reagents and conditions: (a) pyridyl-4-boronic acid, Na2CO3, Pd(PPh3)4, toluene/EtOH, ∆; (b) PtO2, 
H2, MeOH, konc HCl; (c) PrI, K2CO3, CH3CN, ∆; (d) PrI, ∆; (e) PtO2, H2, MeOH, konc HCl. 
 
3.3. Buchwald-Hartwig Cross Coupling between Phenylbromides and Piperazines (Paper III) 
All ortho- and para-substituted, and most meta-substituted, phenylpiperazines included in the data 
set could be obtained from commercially available starting materials via N-alkylation (Scheme 1). 
However, in order to obtain 1-(3-methylsulfonylphenyl)-4-propylpiperazine (49), 4-benzyl-1-(3-
methylsulfonylphenyl)-piperazine (50) and  1-[3-(benzenesulfonyl)phenyl]piperazine (51), the 
corresponding phenylpiperazines had to be synthesized from the phenyl bromides and piperazine 
using the Buchwald-Hartwig cross coupling reaction
114, 115
. This is a C–N palladium-catalyzed 
cross-coupling reaction where the following general mechanism has been proposed: 
 
b, c
45
R=3-SO2CF3, 3-morpholine, 
    3-SO2cPe, 4-SO2Me
     
41 R=3-SO2CF3
42 R=3-morpholine
43 R=3-SO2cPe
44 R=4-SO2Me
46 R=3-SO2cPe
47 R=3-morpholine
48 R=4-SO2Me
d, e
a
35 
 
 
   Figure 11. The proposed mechanism for the Buchwald-Hartwig cross coupling reaction. 
Bidentate ligands are often used in these reactions to improve the yield, minimize the use of catalyst 
and shorten the reaction time.
114, 115
 1-Bromo-3-(methylsulfonyl)benzene and 1-(benzenesulfonyl)-
3-bromo-benzene were coupled with piperazine using Pd2(dba)3 and rac-BINAP in refluxing 
toluene for 15h (Scheme 3). For chelating ligands, oxidative addition occurs directly from the 
ligand-palladium complex forming intermediate I (Figure 11). Deprotonation by base followed by 
amine ligation produces the palladium amide (II). This key intermediate reductively eliminates to 
produce the product (III) and regenerate the catalyst. β-Hydride elimination from intermediate II is 
avoided by the chelating phosphine, producing a 4-coordinate species which hinder the side 
reaction. The yields were 49% and 87%, respectively, without optimizations. 
Scheme 4 
 
 
a
Reagents and conditions: (a) piperazine, NaOt-Bu, Pd2(dba)3, rac-BINAP, toluene, ∆; (b)   
PrI or BnBr, K2CO3, CH3CN, ∆. 
 
R=Me, Ph 49 R=Me, R'=Pr 
50 R=Me, R'=Bn
51 R=Ph, R'=Pr
a, b
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3.4 Conversion of Functional Groups  
3.4.1 Aniline to Morpholine (Paper II). The commercially available 4-(4-piperidyl)aniline was 
used to prepare the desired para-morpholine compound. After N-alkylation with 1-iodopropane, a 
ring-closing reaction around the aniline nitrogen was achieved by a microwave assisted nucleophilic 
substitution using bis(2-chloroethyl)ether in DMF.
116
 Thus, 4-[4-(1-propyl-4-
piperidyl)phenyl]morpholine (52) was obtained through a 2-step synthesis in an overall yield of 
63% (Scheme 5).  
Scheme 5 
 
 
a
Reagents and conditions: (a) PrI, K2CO3, CH3CN, ∆; (b) bis(2-chloroethyl)ether, DMF, MW. 
 
 
3.4.2 Phenols to Mesylates and Triflates (Paper III). The mesylate and triflate groups are often 
used as leaving groups in aromatic substitution reactions but they can also be used in biologically 
active compounds and were found by Sonesson et al. to have beneficial properties in both the 3-
phenylpiperidine and aminotetraline series.
117
 The transformation from the corresponding phenols 
was achieved by addition of triflic anhydride or mesylchloride, respectively, in the presence of 
triethylamine (Scheme 6).
118, 119
       
 
 
 
 
 
 
 
 
 
 
 
52
a, b
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        Scheme 6 
 
a 
Reagents and conditions: (a) HBr (48%), ∆; (b) NEt3, CH3SO2Cl or (CF3SO2)2O, CH2Cl2. 
 
3.4.3 Triflate to Nitrile (Paper III). In the 3-phenylpiperidine series, Sonesson et al.117 provided a 
convenient route to the cyano-analogue from the partial agonist (-)-3-(3-hydroxyphenyl)-1-propylpiperidine 
((-)-3-PPP). The same route was also used to obtain the meta-cyano compound in the 4-phenylpiperidine 
series. Starting from the triflate (63), palladium catalyzed carbonylation
120
 using carbon monoxide and 
methanol furnished the methyl ester (66).  The ester was converted to an amide (67) via a one-step reaction 
using formamide and sodium methoxide in DMF.
121
 The target compound, 3-(4-propylpiperazin-1-
yl)benzonitrile (68), was then obtained through a dehydration of the amide group by phosphorous 
oxychloride in DMF
122
 (Scheme 7).   
 
 
 
 
 
 
 
 
 
53 X=N
54 X=CH
55 X=N
56 X=CH
b
a
55 X=N, R1/R2=H, R3=OH
57 X=N, R1/R3=H, R2=OH
58 X=CH, R1/R3=H, R2=OH
59 X=CH, R1=OH, R2/R3=H
60 X=N, R1=OH, R2/R3=H
61 X=N, R1/R3=H, R2=OSO2Me
62 X=N, R1/R3=H, R2=OSO2CF3
63 X=CH, R1/R3=H, R2=OSO2CF3
64 X=CH, R1=OSO2CF3, R2/R3=H
65 X=N, R1/R2=H, R3=OSO2CF3
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         Scheme 7 
 
a 
Reagents and conditions: (a) Pd(OAc)2/dppp, CO(g), NEt3, MeOH; (b) HCONH2, NaOMe, DMF; (c) 
POCl3, DMF. 
 
3.4.4 Phenols to Alkoxy-groups (Paper II and III). Two different alkoxy compounds were 
synthesized from the corresponding phenols. The iso-propoxy derivate (69) was produced by 
reaction of the 3-hydroxyphenylpiperidine (58) with NaH in DMF and quenching with 2-
iodopropane. Refluxing the para-isomer (56) in acetonitrile with a weak base (K2CO3) and n-
butylbromide produced the n-butoxy analogue (70) (Scheme 8).    
Scheme 8 
 
a 
Reagents and conditions: (a) NaH, i-PrI, DMF; (b) n-BuBr, K2CO3, CHCN. 
 
 
c
63 66 67
68
b a 
 
a or b
56 R1=H, R2=OH
58 R1=OH, R2=H
69 R1=Oi-Pr, R2=H
70 R1=H, R2=On-Bu
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4. Pharmacology 
 
4.1 Methods 
The target compounds were tested both in vivo and in vitro in different pharmacological assays. The 
in vivo models were used to investigate both behaviour and neurochemical effects in freely moving 
rats while the in vitro models were used to measure the binding affinities to the DA D2 receptor and 
MAO enzymes.  
 
4.1.1. In vitro models. The DOPAC levels produced by a pharmaceutically active compound can be 
linked to a number of different targets and as previously mentioned two of these targets are the DA 
D2 receptor and the MAO A enzyme. We therefore measured the affinity to these targets for a 
subset of compounds chosen to provide as much information about the in vitro SAR as possible. In 
addition to pure affinity, the level of intrinsic activity at the D2 receptors is also a determinant for 
the DOPAC levels. Partial D2 agonists in general produce less DOPAC than an antagonist at a dose 
where maximal effects for both are achieved (see Figure 12). The intrinsic activity was measured in 
a functional assay for a few compounds, but the effect in an in vitro model is not necessarily the 
same as in the living system. The efficacy data produced in the D2L-Gαqi5 HEK293 cells can 
therefore differ from the effects observed in vivo. Another indicator of the agonistic property of a 
compound is the ratio between the propensity to displace agonists rather than antagonists from the 
receptor. These two assays have been denoted D2
High
 and D2
Low
, where high is the active state and 
low the inactive state of the receptor. The same compounds that were examined for intrinsic activity 
were also investigated in the D2
High
 and D2
Low
 binding affinity assays and the ratios 
(Ki(D2
Low
)/Ki(D2
High
)) from these studies clearly showed that the included compounds were more 
prone to displace an agonist than an antagonist. This ratio has also been used as a quantitative 
measurement and strong correlations to the results from both in vitro and in vivo assays of intrinsic 
activity have been shown.
123, 124
  
In addition, the affinity to MAO B was investigated for the para-substituted compounds in order 
to clarify which physicochemical properties of the substituent that was important for interaction 
with the respective isozyme. In agreement with previous observations
6
, we also found that affinity 
to MAO B alone was not a contributing factor to the DOPAC levels in the rat.       
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4.1.2. In vivo models. The level of DOPAC in different parts of the brain has been used as a 
measurement of the synthesis and turnover of DA. Striatum is the part of the brain that has the 
strongest correlation to behaviour and DA is the main neurotransmitter affecting locomotor activity. 
Therefore the level of DOPAC in striatum was the biomarker of choice for our in vivo models. Male 
Sprague-Dawley rats from B&K Scanbur (Sollentuna, Sweden) or Charles River (Köln, Germany) 
were used and five groups of animals, four animals per group, where dosed with either saline 
(control) or the test substance in escalating doses (usually up to a 100 μmol/kg). The behaviour was 
recorded using motility meters
125
 and the distance travelled was used as a measurement of the rats 
activity. The rats were decapitated 1h after the injection and the effect of the target compounds on 
the levels of DOPAC was measured by high-performance liquid chromatography on the 
homogenates of the dissected brain. The rats treated with the test compounds were compared to the 
saline treated rats in the same experiment (effect expressed as "% of control"), both with regards to 
the biochemical markers and the locomotor activity (LMA). Several reference compounds have 
been tested in these models in order to compare if the response factors are in agreement with what is 
known from the literature. The effects on striatal DOPAC levels following administration of 
different D2 ligands were as follows: antagonists (e.g. haloperidol (6)) gave sharp increases, full D2 
agonist (e.g. apomorphine) produced decreased levels and partial agonists (e.g. aripiprazole (10) 
(Figure 12), (-)-3PPP (11)) yielded varying levels (100 - ~150% of control) of DOPAC. This is in 
agreement with previously published results from in vivo studies on rat post mortem 
neurochemistry.
126-129
 The dopaminergic stabilizer pridopidine (16) has effects on DOPAC similar 
to an antagonist, although compared to haloperidol, higher doses are required to achieve the 
maximal response (Figure 12). 
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Figure 12. Dose-dependent effects of the DA D2 agonist apomorphine, the partial agonists (-)-3PPP, 
aripiprazole and 3-(1-benzylpiperidin-4-yl)phenol (29), the antagonist haloperidol and the dopaminergic 
stabilizer pridopidine on the DOPAC levels in striatum. 
The effects on the locomotor activity by the different ligands were also in accordance with previous 
observations. Haloperidol and the partial agonists all produced strong inhibition of the normal 
behaviour while apomorphine gave a biphasic effect on locomotor activity (i.e. inhibition at low 
doses and stimulation at high doses). The dopaminergic stabilizer pridopidine (16), on the other 
hand, had no effect on normal exploratory behaviour and partly habituated rats were even mildly 
stimulated.
130
 Pretreatment with amphetamine has often been used as a model of psychosis and the 
induced hyperactivity was blocked by most antipsychotics. However, as seen with the 
antagonists/partial agonists, this goes hand in hand with inhibition of the normal exploratory 
behaviour. Pridopidine (16) has the ability to counteract the amphetamine induced hyperactivity 
without impeding the normal state and this is a central trait of the dopaminergic stabilizers. Analysis 
of perfusates collected from microdialysis probes implanted in the striatum of freely moving rats 
was used to measure the DOPAC and 3-MT levels during a period of 180 min after administration 
of a MAO A inhibitor. The observed effects, with decreases in DOPAC and increased levels of 3-
MT, were in agreement with previous investigations of known MAO A inhibitors.
11
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experiments were carried out in accordance with Swedish animal protection legislation and with the 
approval of the local Animal Ethics Committee in Gothenburg 
 
4.2 Results 
The results from the different assays are included in Table 1. From the in vivo models, only the 
DOPAC levels (presented as % of control) are presented. Additional results can be found in Table 
3, Paper I. The in vitro data from the binding assays are all included.   
Table 1. In vivo levels of DOPAC and in vitro affinities to D2 and MAO  
 
Comp R' X R Pos 
DOPAC, 
% of ctrl 
± SEM
a
 
pKi 
(D2
High
)
b
 
pKi 
(D2
Low
)
b
 
pKi   
(MAO A)
b
 
pKi   
(MAO B)
b
 
71 n-Pr N H None 181 ± 6
 d
 6.3
e
 
 
4.3
d
 
 72 n-Pr CH H None 131 ± 11
 d
 6.8
 e
 
 
5.0
d
 
 60 n-Pr N OH Ortho 270 ± 23
 e
 
    64 n-Pr CH OSO2CF3 Ortho 270 ± 16
 e
 
    73 n-Pr N OMe Ortho 370 ± 24
 e
 7.7
 e
 7.1 <3.2
 e f
 
 74 n-Pr CH OMe Ortho 277 ± 18
† † 
e
 
7.9
 e
 
 
5.6
 e
 
 75 n-Pr N SO2Me Ortho 283 ± 16
 e
 6.2
 e
 
 
<3.2
 e f
 
 76 n-Pr N CN Ortho 313 ± 9
†† e
 
    77 n-Pr N Me Ortho 327 ± 16
 e
 
    78 n-Pr N Cl Ortho 368 ± 19
 e
 
    79 n-Pr CH CF3 Ortho 254 ± 20
 e
 
    16 n-Pr CH SO2Me Meta 265 ± 10
c
 5.1
c
 4.5
 c
 
  29 Bn N OH Meta 108 ± 4
 c
 8.3
c
 7.0
 c
 
  40 Bn CH SO2Me Meta 310 ± 16 
††c
 
6.4
 c
 6.1
 c
 
  45 n-Pr CH SO2CF3 Meta 258 ± 15
 e
 
    46 n-Pr CH SO2c-Pe Meta 170 ± 10
 e
 5.4
 e
 
 
<3.2
 e f
 
 47 n-Pr CH morph Meta 105 ± 7
 e
 
    49 n-Pr N SO2Me Meta 310 ± 16
††c
 6.2
c
 5.9
 c
 3.9
 e
 
 50 Bn N SO2Me Meta 248 ± 10
 c
 6.4
 c
 5.7
 c
 
  51 n-Pr N SO2Ph Meta 152 ± 7
 e
 
    57 n-Pr N OH Meta 260 ± 12
††c
 7.2
c
 6.1
 c
 <3.2
 e f
 
 58 n-Pr CH OH Meta 107 ± 4
†c
 6.5
c
 5.6
 c
 
  61 n-Pr N OSO2Me Meta 254 ± 18
† e
 
    62 n-Pr N OSO2CF3 Meta 285 ± 12
 e
 
    63 n-Pr CH OSO2CF3 Meta 241 ± 6
 e
 
   
Cont. 
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Comp R' X R Pos 
DOPAC, 
% of ctrl 
± SEM
a
 
pKi 
(D2
High
)
b
 
pKi 
(D2
Low
)
b
 
pKi   
(MAO A)
b
 
pKi   
(MAO B)
b
 
68 n-Pr CH CN Meta 275 ± 10
 e
 
    69 n-Pr CH Oi-Pr Meta 112 ± 6
 e
 
    80 n-Pr N OMe Meta 255 ± 16
 e
 6.5
 e
 
 
4.8
e
 
 81 n-Pr CH OMe Meta 140 ± 8
 e
 5.8
 e
 
 
4.7
 e
 
 82 n-Pr N CN Meta 314 ± 17
 e
 6.6
 e
 
 
<3.2
 e f
 
 83 n-Pr N CF3 Meta 315 ± 15
† e
 
    84 n-Pr CH CF3 Meta 260 ± 9
 e
 6.7
 e
 
 
3.9
 e
 
 85 n-Pr N Cl Meta 250 ± 9
 e
 
    86 n-Pr N COMe Meta 221 ± 9
 e
 
    87 n-Pr CH Me Meta 115 ± 7
 e
 
    88 n-Pr CH SO2i-Pr Meta 205 ± 9
 e
 
    89 n-Pr CH Ot-Bu Meta 196 ± 9
 e
 
    90 Bn CH OH Meta 317 ± 13
†† 
c
 
7.4
 c
 6.5
 c
 
  48 n-Pr CH SO2Me Para 94 ± 5
† d
 
  
<3.2
d f
 3.23
 d
 
52 n-Pr CH morph Para 38 ± 2
 d
 
  
5.9
d
 4.89
 d
 
53 n-Pr N OMe Para 72 ± 3
 d
 5.2
 e
 
 
5.9
d
 3.23
d
 
54 n-Pr CH OMe Para 22 ± 1
 d
 4.6
 e
 
 
6.6
d
 3.66
 d
 
65 n-Pr N OSO2CF3 Para 122 ± 3
 d
 
  
4.8
d
 7.48
 d
 
70 n-Pr CH On-Bu Para 41 ± 2
 d
 
  
6.4
d
 5.8
 d
 
91 n-Pr CH CN Para 94 ± 2
 d
 
  
4.0
d
 3.23
 d
 
92 n-Pr CH Cl Para 68 ± 4
 d
 6.0
 e
 
 
5.8
d
 4.42
 d
 
93 n-Pr CH CF3 Para 86 ± 5
 d
 
  
5.2
d
 4.89
 d
 
 
a
Post-mortem biochemistry of levels of DOPAC in the striatum compared to saline control (n = 4) at 1h after 
administration of 100, 
†
50 or 
††
33
 μmol/kg of test compound (the dose where maximum DOPAC response is 
produced). 
b
Negative logarithm of binding affinities (apparent Ki) to human recombinant HEK-293 cells with 
[
3
H]7-OH-DPAT as ligand for D2
High
 and [
3
H]spiperone as ligand for D2
Low
 and to rat cerebral cortex cells 
with [
3
H]Ro 41-1049 as ligand for MAO A and Ro 16-6491 for MAO B. 
c
Data from paper I.
 d
Data from 
paper II.  
e
Data from paper III. 
f
C50 higher than 1 mM = Ki higher than 0.58 mM.
   
 
4.2.1. In Vitro Binding: D2
High
, D2
Low
, MAO A and MAO B and Intrinsic Activity at D2 
Receptors (Paper I-III). The starting point for the development of the new dopaminergic ligands 
in the 4-phenylpiperidine/-piperazine series was the partial agonist 3-(1-benzylpiperidin-4-yl)phenol 
(29) previously reported by Mewshaw et al.
75, 131
 This compound has a high preference for 
displacing agonist over antagonist ligands at the D2 receptor (i.e. high Ki(D2
Low
)/Ki(D2
High
) ratio) 
and has therefore been classified as a potential partial agonist. In analogy with the development of 
S-(-)-OSU6162 (15) from the partial agonist (-)-3-PPP (11), we wanted to modify the key elements 
of 29 that are responsible for its intrinsic activity in order to produce compounds with little or no 
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intrinsic activity but with a sustained agonist-like interaction with the receptor. The portions of the 
molecule that we speculated as being most likely to contribute to stabilization of the active 
conformation were the phenol group, the piperazine and the large, aromatic N-alkyl group. Binding 
affinities of 29 to D2
Low
 and D2
High
 (Table 1) in our hands confirmed Mewshaw's results and in the 
functional assay 29 also showed a relatively high intrinsic activity (Table 2 in paper I), verifying 
that this compound indeed is a partial D2 agonist. Any modification of the key elements in the 
structure led to a loss of efficacy in the functional assay while the Ki(D2
Low
)/Ki(D2
High
) ratio, albeit 
significantly lower than for 29, stayed ≥ 2, regardless of which portions were exchanged. However, 
in vitro assays measuring intrinsic activity can show varying results depending on which model that 
is used and it can therefore be difficult to determine the intrinsic activity observed in vivo with such 
assays.
67, 132
 
Another interesting aspect of the interaction between the receptor and the ligand is the receptor 
kinetics. Many recent publications have presented fast dissociation from the D2 receptor as a 
possible link to atypicality for the DA mediated antipsychotics used in the clinic.
54, 61, 133, 134
 In a 
model using multiple washes of ligand-pretreated D2 cells in order to detect how long it takes for the 
cell to regain responsiveness to DA, all tested compounds in this structural class displayed fast 
dissociation from the receptor (shown in Figure 2 of Paper I and as reported by Dyhring et al.
62
). 
This competitive interaction means that the effect of normal DA surges is less affected, which 
according to the theory would lead to an improved side effect profile. In sharp contrast, haloperidol 
had a slow dissociation, indicating a non-competitive antagonism where the inactive conformation 
of the DA receptor is stabilized and the responsiveness is diminished for a long time.  
These intriguing results led us to a further exploration of how substitution of the phenyl ring 
affects the biological response. In order to investigate the effects of aromatic substitution and type 
of heterocycle, the N-alkyl moiety was set to 1-propyl. The substituent in mono-substituted 
phenylpiperidines/-piperazines can be located in three different positions; ortho, meta or para in 
relation to the heterocycle. All positions were investigated and the effect on the affinity, primarily 
to the D2 receptor, was determined for a selected subgroup. Three compounds with substituents in 
the ortho-position were tested for their affinity to D2 and the electron-donating methoxy group 
yielded a higher affinity than the corresponding electron-withdrawing methylsulfone. The meta-
substituted subclass showed no such differences and the only compound having somewhat higher 
affinity to the D2 receptor was the phenol-piperazine (57, Table 1). For compounds with 
substituents in the para-position, the D2 receptor affinity was lower than for the corresponding 
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ortho- and meta-analogues and it seems that this position is not preferred for the interaction with 
this receptor.   
However, affinity and intrinsic activity at D2 was not sufficient to explain the observed 
neurochemical effects for all compounds and especially the para-substituted subclass differed 
greatly in their in vivo response compared to the other two positions. Their effects on the DOPAC 
levels led us to suspect that they were actually MAO inhibitors rather than D2 ligands, and therefore 
the affinity to the two MAO isozymes was also measured. The affinity, primarily to MAO A, for the 
para-substituted compounds confirmed our hypothesis and moreover a strong correlation between 
the electronic properties of the substituent and the affinity to MAO A was observed. Affinity to 
MAO B was also apparent for a few of these compounds, but the correlation to the in vivo effects 
were absent in this class. Furthermore, in addition to the para-substituted class, MAO A affinity 
could be detected for the ortho- and meta-substituted compounds as well, albeit not as high and 
only secondary to the D2 affinity. MAO A affinity was only measured for a few ortho- and meta-
substituted compounds but the connection between electronic properties of the substituent and 
affinity to MAO A seems to be highly relevant in these positions as well. In order to explore which 
structural motifs that influence the in vitro effects, quantitative models with physicochemical 
descriptors were produced and these are addressed separately.  
The D2 receptor and MAO A are the targets with the most abundant impact on the DOPAC 
response in the brain. However, other targets are involved in the process of synthesis, storage, 
release, reuptake and metabolism of DA. COMT is involved in the metabolism of DA but in 
complete contrast to MAO A, inhibition of this enzyme leads to increased levels of DOPAC and 
decreased levels of 3-MT. However, all of the known COMT-inhibitors (e.g. tolcapone, 
entacapone) are structurally dissimilar to our compounds and it is therefore highly unlikely that this 
mechanism is involved in the observed in vivo effects. Dopamine and norepinephrine transporter 
(DAT and NAT) inhibitors also affect the DOPAC levels in striatum, albeit in general to a much 
lesser degree than compounds acting on the D2 receptor or MAO A. A few of the compounds in the 
data set have been investigated in both DAT and NAT assays where the % displacement at 1 μM 
was determined (Appendix A). The only compounds displaying any relevant affinity are the para-
susbtituted compounds 91 and 92, which have 22% displacement for NET and 36% displacement 
for DAT, respectively. The limited impact on DOPAC and low affinity of our compounds makes it 
unlikely that these targets are of any major importance for the models. As mentioned in the 
introduction, the sequence homology between the TM regions of DA D2 and DA D3 receptors are 
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~75%, making subtype-selective ligands difficult to obtain. Even though we have no data to support 
it, the compounds presented here are most likely affecting the D3 receptor very much the same way 
they affect D2. However, since D3-ligands have no relevant effect on the DOPAC levels, this 
interaction is insignificant for our correlations.
24
                        
 
4.2.2. In Vivo Effects: Neurochemistry and Locomotor Activity. In agreement with the in vitro 
effects, 29 displayed an in vivo profile that can be directly related to partial agonism. The DOPAC 
levels were unchanged within the whole dose range, and this can be attributed to a perfect balance 
of intrinsic activity at the DA releasing presynaptic receptors. As a full agonist produces a 
significant decrease in DOPAC levels compared to the untreated animals, partial agonists yield 
different DOPAC responses dependent on the level of intrinsic activity. In the case of 29 it is 
therefore likely that the activation of the presynaptic receptors is just enough to keep the release of 
DA at a rate comparable to the unaffected system. At the same time, this compound induces a 
strong inhibition of the locomotor activity, which indicates that the normal postsynaptic effect of 
DA is blocked and the agonist property of 29 is too low to stimulate the behaviour.  
When modifying 29 the levels of DOPAC tended to increase dramatically, and as the binding 
affinities simultaneously were diminished (29 has the highest affinity to D2 of all tested 4-
phenylpiperidines/-piperazines), decreased intrinsic activity is the likely explanation. However, in 
contrary to the intrinsic activity data from the in vitro efficacy model, a few of the compounds in 
this subgroup could be expected to have weak intrinsic activity in vivo. For example, 57 has a 
maximum DOPAC response of 260% of control and this level is reached at 33 μmol/kg (higher 
dose does not increase the DOPAC response). This indicates that the presynaptic effects are not 
fully antagonistic, despite the lack of intrinsic activity in the in vitro assay. Similar to 29, 57 also 
induce an inhibition of the normal behaviour and this is most likely linked to the relatively high 
affinity to D2 receptors. In Figure 5 of Paper I a strong correlation between affinity to D2 receptors 
and locomotor activity can be observed. The set of compounds included in this correlation are both 
D2 receptors antagonists and partial agonists and this indicates that the intrinsic activity, unless very 
high, does not affect the behaviour to any relevant degree.  
Even if specific compounds are likely to be partial agonists and the in vivo model can reveal 
this, it is not a feasible method to use DOPAC levels as an indicator of intrinsic activity on the 
whole data set. Firstly, the potency of each compound differs and while some reaches the full effect 
at doses below 100 μmol/kg (the highest dose in the standard interval) others are likely to require 
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higher doses in order to reach the maximum possible response. This issue can be exemplified with 
16, for which the standard dose interval is not sufficient to achieve maximum DOPAC response and 
at a 100 μmol/kg the neurochemical profile could be mistaken for being a product of partial 
agonism. When increasing the dose to 300 μmol/kg, higher DOPAC levels, that instead indicate 
antagonist effects in vivo, are obtained. For 16 it is likely that 100 μmol/kg is not a sufficient dose 
to reach the maximum effect due to the low affinity (Table 1). However, even compounds with high 
affinity in vitro may require higher doses to achieve the maximum effect in vivo, since low 
bioavailability, poor penetration of the blood-brain barrier etc. can lead to low concentrations of the 
compound at the site of action. So unless the maximum DOPAC levels are high enough to rule out 
any intrinsic activity at the highest dose tested (e.g. 78) or the maximum effect is produced at a dose 
below 100 μmol/kg (e.g. 57), the DOPAC response can not by itself be used as an indicator for 
intrinsic activity. Moreover, the affinity and efficacy at D2 receptors are not the only determining 
factors for the DOPAC response and other mechanisms must be considered. In the para-substituted 
class sharp decreases in DOPAC levels was observed and this was concluded to be connected to 
their inhibitory effects on MAO A rather than the effect on D2 receptors. As it has become clear that 
substitution in the ortho- and meta-position also can lead to inhibition of MAO A, and thus a 
depressing effect on the DOPAC levels, it is most likely that we have two separate mechanisms 
producing the in vivo response. In order to more thoroughly investigate what mechanisms are 
connected to the in vivo response, binding data for both D2 receptors and MAO A was acquired for 
a subset of molecules. Using Partial Least Square (PLS) regression
135-137
, the pKi values for D2 and 
MAO A could be set against the DOPAC levels in a multivariate model and to our surprise a very 
strong correlation could be observed between the in vivo and in vitro effects (Figure 13). 
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Figure 13. Relationship between observed versus predicted response in the PLS model of 
log(DOPAC) versus pKi(MAO A) and pKi(D2) for compounds in Table 1 that have binding data 
from both the D2
High
 and MAO A assays. 
 
This correlation led us to suspect that D2 antagonism and MAO A inhibition are the dominating 
mechanisms behind the in vivo data for this structural class and that intrinsic activity at D2 is 
secondary in affecting the DOPAC response.   
Moreover, the position and physicochemical character of the substituent as well as choice of 
heterocycle is clearly of high relevance to both the in vivo and in vitro response. Although some 
SARs can be manifested from the data by qualitative methods, the relatively large data set makes 
the task at hand quite demanding. Thus, in order to further explore the effect of different aromatic 
substituents in different positions as well as the impact the choice of heterocycle has on the 
response, quantitative methods were employed.  
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5. Quantitative Structure Activity Relationships (QSARs) 
The connection between structural motif and biological response in the mono-substituted 
phneylpiperidines/-piperazines is not easily interpreted and the use of qualitative descriptors 
combined with multivariate calculations is a way to illustrate which properties are related to each 
response in an efficient manner. Additionally, these models can be used to predict the response of 
new compounds with a desired pharmacological profile within this structural class. 
 
5.1 QSAR models of in vivo and in vitro responses (Paper III) 
The position of the aromatic substituent is clearly of great importance for both the in vitro and in 
vivo responses and the dataset was built on these premises. In addition, the physicochemical 
property of the substituent and the choice of heterocycle also influence the pharmacological effect. 
We therefore chose to include the following descriptors:  
 A qualitative variable (QV) describing position relative to the heterocycle (i.e. none, ortho, meta 
and para) 
 Descriptors for the whole molecule (i.e. clogP and LClogD)  
 Seven descriptors that together describe the substituent's physicochemical character (i.e. hydrogen 
bond donating/-accepting properties (HD and HA), Hammet's electronic constants (σm and σp), 
group dipole moment (μR), volume (volR) and lipophilicity (π))  
 Number of nitrogen atoms in the heterocycle (RingN) which in effect separates piperidines from 
piperazines.  
QVs are discrete variables that for this model are split into four dummy variables (Rpos = none, 
ortho, meta or para) containing group-belongings (coded as 1 for yes and 0 for no). ClogP is a 
calculated descriptor that describes the lipophilicity of the whole compound. LClogD is an 
experimental descriptor that stems from HPLC retention times at pH 7.4 and therefore combines 
lipophilicity and ionization at physiological conditions. The substituent-descriptors are obtained 
from the literature (σm, σp and μR), calculated (volR and π) or coded as 1, 0.5 or 0 depending on 
their ability to participate in hydrogen bond (HD and HA). Recently published results
80
 indicate that 
chlorine has some hydrogen accepting capacity and it is therefore set to 0.5. 
The chosen descriptors were modelled against the maximum level of DOPAC and the affinity to 
MAO A and D2 receptor respectively, using PLS regression.
135-137
 The DOPAC model have the 
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largest number of observations (43) since in vivo data is present for all compounds in the data set. 
This yields a two component model with a R
2
Y of 0.85 and a Q
2
 of 0.78 which indicate good 
quality and high predictivity, especially for a model based on in vivo data.  
The QSAR models with the in vitro binding affinities to MAO A and D2 receptors, respectively, 
as response have fewer observations than the in vivo model (21 for MAO A and 17 for D2). 
However, the number of observations still supersedes the number of descriptors which is usually 
desirable in order to avoid over-interpretation. For MAO A, a one component PLS regression model 
with R
2
Y = 0.68 and Q
2
 = 0.53 was obtained while the D2 model had two components and R
2
Y = 
0.82 and Q
2
 = 0.54. Comparing the values of Q
2
, it becomes obvious that the in vitro models are 
less predictive than the DOPAC model. This may be related to the previous assumption, that the in 
vivo responses of these compounds are primarily a result of the combined in vitro binding affinities 
to MAO A and D2 receptors. The DOPAC model can therefore be said to describe both the in vitro 
effects simultaneously, which in combination with the larger set of in vivo observations would help 
produce a better model. 
The coefficient plots of the predictive components are a convenient way to interpret the QSAR 
models and get an overview of which structural elements that are important for each response. The 
plots show which descriptors have the highest influence on the response as well as if the influence 
is positively or negatively correlated to the effect. A general rule of thumb is that a descriptor that is 
positive for D2 is also positive for DOPAC while a descriptor that is positive for MAO A is 
negative for DOPAC and vice versa. Thus, the sum of the impact a descriptor has on D2 and MAO 
A is generally reflected in the impact the same descriptor has on DOPAC (Figure 14).  
The position of the substituent is of great importance in all models. The ortho- and meta-
position correlates positively with the DOPAC levels while a negative correlation is observed for 
the para-position (Figure 14). The opposite is true for MAO A affinity, where substitution in the 
para-position is essential for high affinity while ortho and meta have a negative impact. The 
position-effects in the D2 model are similar to those of the DOPAC model, but the meta-position has 
only minimal influence on this response. Taken together, this explains how the location of the 
aromatic substituent is connected to the in vivo and in vitro effects and how these effects are related 
to each other. However, the response is also influenced by the physicochemical character of the 
substituent and the coefficient plots can help us understand these correlations.  
The electronic components (σm, σp and μR) show that electron-withdrawing properties are 
positively correlated to the DOPAC response, negatively correlated to the MAO A affinity and of 
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minor importance to the affinity to D2 receptors (Figure 14). This indicates that compounds with 
electron withdrawing groups have lower MAO A affinities, and with that higher DOPAC levels, 
compared to the compounds substituted with electron donating groups.  
The size of the substituent (volR) affects the DOPAC response negatively and according to the 
coefficient plots from the in vitro models, this is related to a diminished binding to D2. Larger 
groups are not well accepted according to the DOPAC response and a poor fit in the active site of 
the D2 receptor is a possible explanation. The phenylsulfone (51) moiety is predicted to produce 
high DOPAC levels, probably linked to the fact that it is a piperazine-analogue with electron-
withdrawing properties of the meta-substituent (both are positive for DOPAC increase). However, 
the observed response is much weaker than predicted (Figure 3, Paper III) and it is likely that this 
effect is connected to the size of the substituent.  
Hydrogen donating/accepting properties are not a major determinant for the most part, but in the 
D2 model the hydrogen donating groups yield high affinity. This can be directly related to the 3-
hydroxyl group, which in general makes good substrates of dopamine-like compounds. However, 
the influence of HD on DOPAC is not in proportion to the influence on D2 and this deviation is a 
further indication that the phenol contributes to intrinsic activity.  
Lipophilicity (π and clogP) has a substantial positive impact on the MAO A affinity and no 
relevant influence on D2 affinity. Following the general relationship, this would lead to lipophilicity 
having a negative correlation to DOPAC and yet the DOPAC response is not affected by this 
property. It is a common phenomenon that highly lipophilic compounds have better affinity to 
different targets in vitro than more polar analogues. However, this is not always relevant to the 
effect these compounds have in a living system. Plasma protein binding and the propensity to be 
metabolized by liver enzymes are only two examples of in vivo related mechanisms that may 
counteract the overall effect of a lipophilic compound, even if the interaction with the target itself is 
optimal. However, what abolishes the effect of lipophilicity on the DOPAC response in this case 
remains to be investigated. 
The number of nitrogen atoms in the ring shows a positive correlation to DOPAC and these 
effects are related to the impact the choice of heterocycle has on both MAO A and D2 affinity. 
Piperazines have lower affinity to MAO A than the piperidines which are manifested by the 
negative bar in the coefficient plot from the MAO A model (Figure 14). The opposite is true for D2 
were piperazines tend to have higher affinity than the piperidines. Thus the negative correlation 
between MAO A and DOPAC together with the positive correlation between D2 and DOPAC make 
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the in vitro effects of this property additive towards the in vivo response. The experimental 
descriptor LClogD is also highly affected by the choice of heterocycle. The retention time from 
HPLC which this descriptor is based on is to a large extent affected by the level of ionization of the 
tested compound. Piperazines and piperidines have different pKa values and the ionization at 
physiological pH therefore differs, subsequently leading to variations in the retention time. 
Piperazines have lower pKa than the corresponding piperidines and are therefore less ionized at pH 
7.4. This in turn leads to longer retention-times which are expressed as higher LClogD-values 
(method for calculating LClogD is described in the method-section of Papers II and III). Albeit 
highly influential, the level of ionization is only in part determining the retention-time in the HPLC. 
Lipophilicity of the compound is also a major contributor and since the column used in the method 
is llipophilic (reversed phase), more lipophilic compounds yields higher values. LClogD can 
therefore be said to be the sum of the lipohilicity of a compound and its propensity to be ionized at 
physiological pH and these two properties are basically described by clogP and Ring N. This also 
become obvious when observing the coefficient plots, where the direction and significance of the 
LClogD-descriptor is more or less the sum of clogP and Ring N.  
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Figure 14. PLS coefficient plots of the predictive components from each of the QSAR models with 
DOPAC, D2 and MAO A, respectively, as response.  
 
5.2 Development of new electronic descriptors (Paper IV) 
The relationship between electronic properties of the substituent and the DOPAC response made us 
interested in further investigating these effects. The most common descriptors in QSAR modelling 
are the Hammet's constants σm and σp. Although useful in describing basic electron-
withdrawing/donating properties, these descriptors are not developed for explaining the 
physicochemical character of substituted aromatics in a biological system but rather the reactivity of 
an aromatic carboxylic acid with the substituent located in the meta- (σm) or para- (σp) position. In 
addition, the Hammett constants are derived experimentally and therefore values for substituents 
that are not tabulated in the literature will be difficult to obtain. On these premises we sought to find 
an alternative to the classical constants using quantum mechanical calculations to get descriptors 
DOPAC
D2
MAO A
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that were interpretable, calculable and significant for use in QSAR models. The method used to 
calculate these new descriptors is described in the methods section of Paper IV. 
The calculated descriptors were assessed in order to reproduce σm, σp and the absolute value of 
the group dipole moment (µ) in a PLS regression model. This analysis clearly showed that the two 
sets of descriptors are highly correlated (see Figure 4 in Paper IV) and we therefore decided to 
exchange the common electronic descriptors in each of the QSAR models for DOPAC, D2 and 
MAO A with these new descriptors, while leaving all the other parameters unaffected. The new 
models are very similar to the original models in terms of R
2
Y and Q
2
 and the combined plots of 
observed versus predicted DOPAC models, with the classical or the new electronic descriptors, 
shown in Figure 15 is a good illustration of the existing correlations. In addition, the impact of the 
electronic properties in each of the in vitro models was investigated by removing the electronic 
descriptors and regenerating the model without them. In the D2 model, the predictivity (Q
2
) actually 
increased when the electronic descriptors were removed, while for the MAO A model a sharp 
decrease in Q
2
 followed the exclusion (see Table 2, Paper IV). These results gave further support to 
the previously established theory, that electronic properties are important mainly for the affinity to 
MAO A and that this is the main mechanism behind the influence of electronic properties on the 
DOPAC response.   
 
 
Figure 15. The observed versus predicted levels of DOPAC in striatum as log(percent of control). Green: 
QSAR based on QM descriptors. Blue: The Pettersson et.al QSAR based on empirical parameters. 
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6. Ligand-Target interactions at MAO A and D2 receptors 
The interaction between the para-substituted phenylpiperidines/-piperazines and the MAO A 
enzyme was exemplified by compound 54, which was fitted in the active site by means of 
molecular modelling based on an X-ray crystal structure of MAO A (Figure 4, Paper II). This model 
revealed a hydrophobic pocket in which the aromatic substituent fitted while an interaction between 
the methoxy-oxygen and Cys323 further stabilized the complex. The binding pose of 54 is very 
similar to the 4-substituted phenethylamines presented by Gallardo-Godoy et al.
138
 and it is 
interesting to compare how substitution in other positions of the aromatic ring affects the MAO A 
affinity in the two structural classes. The 2- and 3-position of the phenethylamines are unfavourable 
compared to the 4-position, very much like substitution in ortho- or meta-position in the 
phenylpiperidines/-piperazines are unfavourable compared to the para-substituted analogues. 
Gallardo-Godoy et al. proposed that sterically disfavoured areas, especially where the 3-substituents 
are located, led to the diminished affinity. The substituents in the phenethylamine series are 
primarily alkoxy-groups and a comparison of positional effects with the methoxy-substituted 
phenylpiperidines (74, 81 and 54) reveal that affinity to MAO A follow the same trend in both 
structural classes (i.e. para>ortho>meta). The same relationship is however not seen with the 
phenylpiperazines, where a methoxy-group in the ortho-position (73) rendered a compound inactive 
in the MAO A assay while the corresponding meta-analogue (80) had the same affinity as the 
piperidine. Gallardo-Godoys group proposed a π-π stacking interaction between the aromatic ring of 
the phenethylamines and Phe208 in the active site of MAO A and thus a possible explanation to the 
deviating effects of the phenylpiperazines is a different character of the π-system. Since a lone pair 
on the anilinic nitrogen is partly delocalized, the π-π stacking interaction between the aromatic ring 
and the MAO A receptor may be disturbed, leading to a generally weaker interaction. Another 
possibility is that the angle between the phenyl and heterocyclic rings are important for the 
interaction with MAO A and since these differ in the low-energy conformations of phenylpiperidine 
and phenylpiperazine (see below), this could affect the affinity. Regardless of the reason, it is likely 
that the phenylpiperidines and phenethylamines interact with the active site of MAO A in a similar 
fashion while in the phenylpiperazine class some of these interactions are different.  
The interaction between the ligand and the D2 receptor is decisive for both the affinity and 
intrinsic activity and it is therefore of interest to elucidate what structural motifs in the 
phenylpiperidines/-piperazines that are important for both these properties. We have concluded that 
3-(1-benzylpiperidin-4-yl)phenol (29) has high affinity to D2 receptors and intrinsic activity both in 
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vitro and in vivo. The structural properties that we expected to be responsible for these effects are 
the phenylic 3-hydroxyl group, the piperazine and the N-benzyl. The 3-hydroxyl group is a mimic 
of the catechol in dopamine and therefore an important motif in the interaction with the D2 receptor. 
Exchanging this group with a methylsulfon (50) leads to lower affinity to both D2
Low
 and D2
High
, a 
major drop in the Ki
Low
/Ki
High
 ratio and a complete loss of intrinsic activity in vitro. It is therefore 
safe to say that the phenol in 29 is highly involved in the stabilization of the active conformation of 
the D2 receptor. The distance between the aromatic ring and the nitrogen atom of the basic amino 
group differ between DA and phenylpiperidines/-piperazines and thus the compounds in our data 
set are less "dopamine-like" than compounds based on the phenethylamine backbone (e.g. the 3-
phenylpiperidines described by Sonesson et al.
139
). Studies have shown that for the 4-
phenylpiperidines, the most stable conformation is when the piperidine ring and the aromatic ring 
are perpendicular to each other, while for phenylpiperazines co-planarity between the piperazine 
and aromatic ring is the most stable conformation (due to the sp
2
 hybridization of the anilinic 
nitrogen).
131, 140
 Rotation from these conformations in order to get a better fit in the receptor costs 
energy and such "energy-penalties" are associated with lower affinities and less intrinsic activity.
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It is therefore likely that the angle between the phenyl and piperidine in 90 is less optimal for the 
ligand-receptor interaction than it is for the corresponding piperazine (29) and that this is the reason 
for the lower affinity and less intrinsic activity of 90. We have also made MMF94S energy 
minimization studies
141, 142
 on the 3-hydroxypiperazine (57) and 3-methylsulfonpiperidine (16) in 
order to compare the angle between the aromatic ring and the heterocycle for the low energy 
conformations. These studies show that, in accordance with previous studies, the phenyl and 
piperazine rings are co-planar while the phenyl and piperidine are perpendicular (Figure 16).  
 
 
Figure 16. The 3D structures of 16 (left) and 57 (right) in their respective low energy conformation. 
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The piperazines in general have higher affinity to D2 receptors than the corresponding piperidines 
and the in vivo effects also reflect this. Therefore the angle between the aromatic ring and the 
heterocycle is likely to be important and may suggest that the stable conformation of the piperazine 
is more optimal for the interaction with the DA D2 receptors compared to the piperidines. There are 
however some deviations from this rule. The unsubstituted and the ortho-methoxy substituted 
phenylpiperidines (i.e. 72 and 74, respectively) have higher affinity to D2 receptors than the 
corresponding phenylpiperazines (71 and 73, respectively). Lacking substituents in the aromatic 
ring (i.e. no substituent in the meta-position that needs to recognize an interaction-point in the 
receptor) leaves the hydrophobic interactions as the most important factor for stabilization of the 
ligand receptor complex. These interactions are likely to be less sensitive to an optimal 
conformation of the piperidine/piperazine which would eliminate the energy-penalty, and thus the 
lower affinity, for the phenylpiperidine. In addition, other properties, such as lipophilicity, would 
become more important for the affinity and that may be the reason for the more lipophilic piperidine 
to bind harder than the corresponding piperazine. In a study by Dijkstra et al.
140
, the conformation 
of arylpiperidines/-piperazines with substitution in different positions has been studied and it is 
obvious that the orientation between the aryl and heterocyclic rings is highly influenced by the 
location of the substituent. Ortho-substitution inevitably forces the heterocycle towards a 
perpendicular orientation in relation to the aryl, regardless of whether the heterocycle is a piperidine 
or piperazine. This means that the ortho-substituted phenylpiperidine/-piperazine all have the same 
phenyl-heterocycle conformation and therefore no major difference in affinity to D2 are observed.   
The N-alkyl group is also of some importance as exchanging the benzyl in 29 to a propyl-group 
(57) led both to a diminished affinity and a loss of intrinsic activity in vitro. The same replacement 
for the corresponding piperidines (90 and 58) also led to an attenuated affinity, indicating that the 
extra aromatic ring is beneficial for the ligand-receptor interaction in the phenol series. However, 
for the methylsulfones, the drop in affinity was not observed for the piperazines (50 and 49) 
whereas for the piperidines (40 and 16), the N-alkyl effect was similar to the phenols. This is further 
implications that interactions between specific parts of the ligands and the receptor are more or less 
important depending on which other interactions are present.  
Even if the in vitro model shows no intrinsic activity for the tested N-propyl analogues, the in 
vivo data indicate that some of the meta-substituted compounds are likely to act as partial agonists. 
Due to the structural resemblance to the ligands modelled in the D3 receptor by Newman et al.
79
, we 
decided it to be relevant to use this work as a reference for the proposed interactions of the 
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compounds in our data set. However, the interaction between the meta-chloro of 2,3-
dichlorophenylpiperazine and Ser194 (5.43) on TM5 that Newman et al. has claimed to lead to a 
stabilization of the active conformation of D3, is depending on the absence of N-alkyl on the 
piperazine. With an N-alkyl group present the compounds in this model got twisted in such a way 
that the bond between the chlorine and oxygen could not be formed. Yet even with an N-alkyl group 
as long as butyl, some intrinsic activity could be detected in the Go BRET assay, indicating that the 
receptor was not completely stabilized in the inactive conformation. In the same model, the 2-
methoxyphenylpiperazine could not interact with the serine in a way that led to a stabilization of the 
active conformation and subsequently the intrinsic activity was lower than for the corresponding 
dichloro-analogue. The homology between D2 and D3 is high with similar 3D conformations, but 
some differences have been observed, especially in the extracellular loop regions.
68
 Since some of 
the meta-substituted compounds in our series are thought to act as partial agonists at D2 while the 
ortho-substituted compounds all have antagonist profiles, we expect that the ligand-receptor 
interaction of our compounds is similar to the Newman model.  
Besides the intrinsic activity, the in vivo response is influenced by both the affinity to MAO A 
and the potency at D2 receptors and it is therefore hard to decide if a compound acts as a partial 
agonist based on the DOPAC levels alone. However, the meta-hydroxyl compounds 57 and 58 are 
likely to have intrinsic activity based on their affinity to MAO A/D2 and DOPAC levels (although 
58 have only been tested in vivo up to 50 μmol/kg) and 57 also has lower DOPAC than predicted in 
the in vivo/in vitro correlation (Figure 13). The hydroxyl-group is both a good hydrogen bond donor 
and acceptor and a hydrogen bond to a serine or a histidine residue in the active site, leading to a 
stabilization of the active conformation of D2, is therefore likely. And if this is possible for the 
meta-hydroxy compounds, other analogues with hydrogen-bonding meta-substituents could also 
interact in this manner.  
The π-π interactions are an important class of noncovalent ligand−receptor interactions and have 
been proposed to be involved in the stabilization of the active conformation of D2.
73, 92, 143-145
 A 
good example of this is (S)-dipropyl-2-aminotetralin (S-DPAT), which lack aromatic substituents 
but is still a full DA D2 agonist.
56, 58
 Furthermore, the electron withdrawing/donating properties of 
aromatic substituents are related to the electron density of the aromatic ring, which in turn has an 
impact on the proneness of the ring to participate in a π-π interaction.146, 147 In the 
phenylpiperidine/-piperazine class, it is possible that the electronic properties of the substituents 
affect the ability of the aromatic ring to π-interact with the receptor and thus influence the intrinsic 
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activity. Although the impact of the electronic properties on the DOPAC response is connected 
primarily to the MAO A affinity, intrinsic activity could be an additional link in the relationship 
between structure, in vivo response and in vitro response.  
Compound 16 has been fitted in the active site of the D2 receptor using the docking method 
published by Malo et al.
92
 (Figure 17) and according to this model the oxygen atoms in the 
methylsulfone-group show possible hydrogen bond interactions with both Ser193 and His393 while 
the protonated nitrogen interacts with Asp114. In addition, a hydrophobic interaction is feasible 
between the phenyl ring of the ligand and Phe389 in the binding site. The "agonist-fit" of 16 
together with the low affinity is the likely reasons for the unique profile of this compound. Since 16 
prefer the high-affinity state of the D2 receptor it is more prone to bind when DA is present and it is 
also able to displace the endogenous ligand. However, once DA is displaced, the low affinity of 16 
enables it to leave the receptor quickly and thus make way for DA to bind again. The impact on 
normal DA surges is therefore minimal while the hyperdopaminergic states can be efficiently 
inhibited. 
 
         
 
Figure 17. Pridopidine (16) in the active site of D2 with possible interactions to aromatic acids marked 
(dotted lines). 
 
 
 
Phe389
His393
Ser193 Asp114
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7. Concluding remarks 
A set of mono-substituted 4-phenylpiperidines and 4-phenylpiperazines have been synthesized and 
evaluated in vivo and in vitro for their effect on the dopaminergic system. The levels of DOPAC in 
striatum were measured for all compounds and the behavioural effects were reported for a chosen 
subset. Binding affinities to D2 and MAO A as well as intrinsic activity and receptor kinetics was 
determined for some of the compounds in order to investigate the mechanisms behind the in vivo 
effects. Based on these data, the structural requirements for intrinsic activity at D2 in this class of 
compounds have been elucidated and a method for obtaining D2 antagonists which preferentially 
displaces an agonist over an antagonist and have fast dissociation rates from the receptor are 
described. This has also led to the discovery of the dopaminergic stabilizer pridopidine which has 
been shown to display low affinity and surmountable D2 antagonism with a preference for binding 
to the active conformation of the receptor. These properties, together with a fast dissociation rate 
once bound to the receptor, would allow an attenuated physiological neurotransmission to persist in 
the normal state while hyperdopaminergic conditions are effectively inhibited. 
In addition, QSAR models with physicochemical descriptors set against the different 
pharmacological responses (i.e. DOPAC, Ki(D2) and Ki(MAO A)) have led to an improved 
understanding of how the observed effects are related. A strong correlation between the affinities to 
D2 and MAO A and the levels of DOPAC in striatum has been established and the structural 
properties that are linked to each response have been annotated. The location of the aromatic 
substituent have proven utterly important for the pharmacological effects and distinct properties, 
such as D2 antagonism, D2 partial agonism and MAO A inhibition, can be produced by substituting 
different positions with functional groups of altering physicochemical properties. An electron-
donating substituent in the para-position produces a MAO A inhibitor, having only minor 
interactions with the D2 receptor. Any substituent in the ortho-position yields a D2 antagonist while 
the meta-substituted compounds are more diverse, acting either as D2 antagonists or partial agonists. 
Although the ortho- and meta-substituted compounds mainly affect the D2 receptor, they can also 
have some MAO affinity depending on the physicochemical properties of the substituent. 
The QSAR models and assimilated understanding of the mechanisms underlying the in vivo 
effects can be used to discover novel dopaminergic ligands with a desired pharmacological profile 
and future use as CNS active drugs for a wide variety of diseases and symptoms.   
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9. Appendices 
Appendix A 
 
Table A1. Singlepoint displacement data of selected compounds on  
DAT and NET 
Compound 
DAT (h) 
(1μM) 
NET (r) 
(1μM) 
NET (h) 
(1μM) 
16 
 
9 
 
47 
 
10 
 
48 6 
 
-1 
54 -9 
 
11 
68 
 
-12 
 
73 -5 
 
-4 
76 7 
 
-3 
82 
 
-13 
 
83 -12 
 
-4 
84 -2 -9 0 
91 -2 
 
22 
92 36 
 
11 
93 -3 
 
5 
The results are expressed as a percent of control specific binding obtained in the presence of 
the test compounds from the assays listed below. Data are obtained from Cerep (Poitiers, 
France). 
 
Assay 
Reference Compound IC50 (M) Ki (M) nH 
 
 
NE transporter (h) 
protriptyline 5.5E-09 4.1E-09 1.4 
 
 
DA transporter (h) 
BTCP 1.1E-08 5.6E-09 1.2 
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